Circular Genomics
Circular Genomics, Inc. is a global leader in the development of circular RNA (circRNA) biomarkers, focusing on precision neurology and psychiatry. The company specializes in creating innovative blood-based diagnostic tools for neurological disorders, including Alzheimer's disease, aiming to enhance diagnostic accuracy and predict disease progression.
Leadership & Board
- Current Number of Employees
- 19
- Current LinkedIn Followers
- 7,869
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $15M
- Total Funding Rounds
- 2
- Latest Funding Amount
- $15M
- Latest Funding Round
- Series A
- Post-Money Valuation
- ―
Company Momentum Positive
Circular Genomics LinkedIn following is increasing, signaling rising market interest, but its workforce is shrinking indicating potential contraction.
Employee Trend
Circular Genomics had 19 employees as of October 12, 2026. The number of employees increased by 1 (5.56%) week-over-week.
Social Trend
Circular Genomics had 7,869 followers as of October 12, 2026. The number of followers increased by 23 (0.29%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Dec 01, 2025 | Series A | $15.00M | ― |
| Jul 08, 2025 | Investment | $250.00K | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Alzheimer's Drug Discovery Foundation | Series A |
| Mountain Group Partners | Series A |
| Poplar Grove Investors | Series A |
| HIP Fund | Series A |
| Alzheimer's Drug Discovery Foundation | Investment |
Similar Companies
A snapshot of private companies similar to Circular Genomics, helping you discover and navigate related company profiles.
Related News and Analysis
